We use cookies for a better user experience. Read our Privacy Policy

I Agree

Psoriatic Arthritis Therapeutics Market

Psoriatic Arthritis Therapeutics Market (Drug Class: TNF Inhibitors, Interleukin Inhibitors, PDE4 Inhibitors, and Others; Route of Administration: Oral, Parenteral, and Topical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Market Outlook 2031

  • The global psoriatic arthritis therapeutics market was valued at US$ 10.8 Bn in 2021
  • The global market is projected to grow at a CAGR of 8.0% from 2022 to 2031 and to reach more than US$ 24.2 Bn by the end of 2031

Analysts’ Viewpoint on Market Scenario

A large patient population is suffering from moderate to severe psoriatic arthritis, and the number is increasing across the globe. This presents significant opportunities to manufacturers in the global market. The global psoriatic arthritis therapeutics market is driven by extensive research to provide treatments and to relieve the symptoms of the condition.

Leading pharmaceutical companies are striving to address the unmet medical needs of severe psoriatic arthritis patients through new product development. Large number of small molecules and biologic products are under different phases of clinical trial for the treatment of psoriatic arthritis. Companies have made significant investments in clinical R&D and have established strategic partnerships and collaborations to accelerate new product development.

Psoriatic Arthritis Therapeutics Market

Psoriatic Arthritis Therapeutics Market Introduction

Psoriatic arthritis is a type of seronegative spondyloarthritis that is distinguished by inflammatory arthritis in conjunction with psoriasis. Psoriatic arthritis has a wide range of clinical manifestations, but the axial joints and distal interphalangeal joints are frequently involved. Interleukin inhibitors drugs have proven to be effective and well-tolerated treatment for psoriatic arthritis, and recently, around three different interleukin inhibitors have been approved and commercialized in the U.S. and Europe. Several different drug candidates are in phase III clinical trials for psoriatic arthritis treatment. These are likely to be commercialized in first half of the forecast period.

Request a sample to get extensive insights into the Psoriatic Arthritis Therapeutics Market

High Prevalence and Increase in Incidence Rate of Psoriatic Arthritis to Drive Global Market

The global psoriatic arthritis therapeutics market is driven by high prevalence and increase in incidence rate of psoriatic arthritis. Patients with skin condition psoriasis have a high risk of developing psoriatic arthritis, and the number of patients has steadily increased in the last few years. People are living stressful lives, which results in overstimulation of immunity of the human body. This increases the number of patients with psoriasis, primarily the geriatric population. In the U.S., around 7.5 million people are affected with psoriasis, and around 30% of them are affected with psoriatic arthritis. Therefore, high prevalence and increase in the incidence rate of psoriasis and psoriasis led arthritis across the globe are driving the global psoriatic arthritis therapeutics market demand.

Novel Pipeline Drugs to Propel Global Market

For the treatment of psoriatic arthritis, a large number of small molecules and biologic products are in various stages of clinical trials. Leading companies have made significant investment in clinical R&D and have formed strategic partnerships and collaborations to accelerate the development of new products. Interleukin inhibitors have been shown to be an effective and well-tolerated treatment for psoriatic arthritis, and three different interleukin inhibitors have recently been approved and commercialized in the U.S. and Europe. New therapeutic drug classes, such as Bristol Mayer Squibb’s TYK2 kinase inhibitor-BMS-986165, and AbbVie’s JAK inhibitor- Upadacitinib (ABT-494), are currently in phase III clinical trials for psoriatic arthritis. Hence, approval and commercialization of novel therapeutic drugs under clinical trial studies is projected to propel the global market during the forecast period.

Request a custom report on Psoriatic Arthritis Therapeutics Market

Higher Efficacy Rate Fueling TNF Inhibitors Segment

In terms of drug class, the TNF inhibitors segment accounted for the largest share of the global market in 2021. Higher efficacy rate than small molecules, fewer alternative therapeutic drugs, and high cost are expected to drive the TNF inhibitors segment during the forecast period. Furthermore, the segment is expected to be propelled by increase in the rate of adoption of biosimilar drugs in developed countries and rise in demand in emerging markets during the forecast period.

Large Number of Prescriptions of Biologic Drugs Bolstering Parenteral Segment

Based on route of administration, the global market has been classified into oral, parenteral, and topical. The parenteral segment held major share of the global market in 2021. High cost and high volume prescription of biologic drugs, which are administered via intravenous and subcutaneous injections, are ascribed to the segment's large market share.

Hospital Pharmacies to Increase Market Size Around Globe

In terms of distribution channel, the hospital pharmacies segment dominated the global market in 2021. This is ascribed to increase in the number of hospital admissions for psoriatic arthritis and high treatment cost. Pipeline biologic products of leading biopharmaceutical companies are likely to receive approval and commercialization in the near future. Biologic drugs are commonly and easily available at hospital pharmacy stores. Therefore, expected launch and commercialization of biologic therapeutic drugs for psoriatic arthritis are likely to augment the hospital pharmacies segment during the forecast period.

Regional Outlook

As per global psoriatic arthritis therapeutics market forecast, North America is expected to be a highly lucrative market for psoriatic arthritis therapeutics during the forecast period. High prevalence of psoriatic arthritis, increase in adoption of biologic drugs for the treatment of moderate to severe psoriatic arthritis, and anticipated new product approvals are likely to fuel the market in North America.

The market in Asia Pacific is projected to grow at a high CAGR during the forecast period. Increase in awareness about psoriatic arthritis, rapidly changing health care infrastructure, rise in access to psoriatic arthritis pharmacotherapy and arthropathic psoriasis therapy in developing countries such as China and India, well-established pharmaceutical market in Japan, and surge in adoption of biologic drugs in Australia and New Zealand are anticipated to fuel the market in Asia Pacific during the forecast period.

Large base of biopharmaceutical companies, new product development and commercialization, increase in the adoption of biologic products, and high per capita health care expenditure in Germany and France are likely to bolster the psoriatic arthritis therapeutics market in Europe from 2022 to 2031.

Rise in purchasing power of the middle class patient population, increase in the incidence of psoriatic arthritis, and surge in launch of new biosimilars & biologic drugs are expected to propel the market in Latin America during the forecast period.

Analysis of Key Players in Global Psoriatic Arthritis Therapeutics Market

The global market is fragmented, with the presence of a large number of leading players. Key players operating in the global medical education market are AbbVie, Inc., Janssen Pharmaceutical NV, Novartis AG, Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, and UCB S.A. These players are adopting growth strategies such as new product development, product launches, product approval, agreement, partnerships, and merger.

Key Developments

  • In September 2022, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) oral treatment for adults with moderate-to-severe plaque psoriasis. It is the first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor.
  • In December 2021, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Key players have been profiled in the psoriatic arthritis therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Psoriatic Arthritis Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 10.8 Bn

Market Forecast Value in 2031

More than US$ 24.2 Bn

Growth Rate

8.0%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

Market share analysis by company (2021)

Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • TNF Inhibitors
    • Interleukin Inhibitors
    • PDE4 Inhibitors
    • Others
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Companies Profiled

  • AbbVie, Inc.
  • Janssen Pharmaceutical NV
  • Novartis AG
  • Amgen, Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • UCB S.A

Customization Scope

Available upon request

Pricing

Available upon request

Psoriatic Arthritis Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global psoriatic arthritis therapeutics market in 2021?

The global market was valued at US$ 10.8 Bn in 2021.

How big will be the global market in 2031?

The global market is projected to reach more than US$ 24.2 Bn by 2031.

What was the CAGR of the global market from 2017 to 2021?

The global market advanced at a CAGR of 15.7% from 2017 to 2021.

What will be the CAGR of the global psoriatic arthritis therapeutics industry during the forecast period (2022–2031)?

The global market is anticipated to rise at a CAGR of 8.0% from 2022 to 2031.

What are the prominent trends that affect market growth?

Increase in demand for biologics, new product approvals, and high prevalence & increase in incidence rate of psoriatic arthritis.

Which region is likely to account for major share of the global market during the forecast period?

North America is expected to account for the largest share of the global market during the forecast period.

Who are the prominent players in the global psoriatic arthritis therapeutics market?

AbbVie, Inc., Janssen Pharmaceutical NV, Novartis AG, Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, and UCB S.A.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriatic Arthritis Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

        4.4.2. Market Volume/Unit Shipments Projections

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Disease Prevalence & Incidence Rate globally with key countries

    5.2. Pipeline Analysis

    5.3. Key Mergers & Acquisitions

    5.4. Covid-19 Impact Analysis

6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. TNF Inhibitors

        6.3.2. Interleukin Inhibitors

        6.3.3. PDE4 Inhibitors

        6.3.4. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Oral

        7.3.2. Parenteral

        7.3.3. Topical

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Psoriatic Arthritis Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. TNF Inhibitors

        10.2.2. Interleukin Inhibitors

        10.2.3. PDE4 Inhibitors

        10.2.4. Others

    10.3. Market Value Forecast, by Route of Administration, 2017–2031

        10.3.1. Oral

        10.3.2. Parenteral

        10.3.3. Topical

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Psoriatic Arthritis Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. TNF Inhibitors

        11.2.2. Interleukin Inhibitors

        11.2.3. PDE4 Inhibitors

        11.2.4. Others

    11.3. Market Value Forecast, by Route of Administration, 2017–2031

        11.3.1. Oral

        11.3.2. Parenteral

        11.3.3. Topical

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. TNF Inhibitors

        12.2.2. Interleukin Inhibitors

        12.2.3. PDE4 Inhibitors

        12.2.4. Others

    12.3. Market Value Forecast, by Route of Administration, 2017–2031

        12.3.1. Oral

        12.3.2. Parenteral

        12.3.3. Topical

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Psoriatic Arthritis Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. TNF Inhibitors

        13.2.2. Interleukin Inhibitors

        13.2.3. PDE4 Inhibitors

        13.2.4. Others

    13.3. Market Value Forecast, by Route of Administration, 2017–2031

        13.3.1. Oral

        13.3.2. Parenteral

        13.3.3. Topical

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. TNF Inhibitors

        14.2.2. Interleukin Inhibitors

        14.2.3. PDE4 Inhibitors

        14.2.4. Others

    14.3. Market Value Forecast, by Route of Administration, 2017–2031

        14.3.1. Oral

        14.3.2. Parenteral

        14.3.3. Topical

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. AbbVie, Inc.

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Janssen Pharmaceutical NV

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Novartis AG

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Amgen, Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Celgene Corporation

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Eli Lilly and Company

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. UCB S.A

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Bristol Myers Squibb

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Other Prominent Players

List of Tables

Table 01: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 08: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 12: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 16: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 20: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 24: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Psoriatic Arthritis Therapeutics Market Snapshot

Figure 02: Global Psoriatic Arthritis Therapeutics Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031

Figure 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2017-2031

Figure 05: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration (2021)

Figure 06: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2021)

Figure 04: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class (2021)

Figure 07: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Region (2021)

Figure 08: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 09: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 10: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2021–2031

Figure 11: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2021–2031

Figure 12: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2021–2031

Figure 13: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021–2031

Figure 14: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 15: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 16: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2021–2031

Figure 17: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2021–2031

Figure 18: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2021–2031

Figure 19: Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2031

Figure 20: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2021-2031

Figure 21: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2021–2031

Figure 22: Global Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2021–2031

Figure 23: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021-2031

Figure 24: Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region, 2017 and 2031

Figure 25: Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

Figure 26: North America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 27: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country, 2017 and 2031

Figure 28: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 29: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031

Figure 30: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 31: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

Figure 32: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 33: North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031

Figure 34: North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 35: Europe Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 36: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 37: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 38: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031

Figure 39: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 40: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

Figure 41: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 42: Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031

Figure 43: Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 44: Asia Pacific Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 45: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 46: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 47: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031

Figure 48: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 49: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

Figure 50: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 51: Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031

Figure 52: Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 53: Latin America Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 54: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 55: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 56: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031

Figure 57: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 58: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

Figure 59: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 60: Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031

Figure 61: Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 62: Middle East & Africa Psoriatic Arthritis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2021–2031

Figure 63: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 64: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 65: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2021 and 2031

Figure 66: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by drug Class, 2022–2031

Figure 67: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

Figure 68: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 69: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2021 and 2031

Figure 70: Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 71: Global Psoriatic Arthritis Therapeutics Market Share Analysis, by Company (2021)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

597

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved